Unveiling Regulatory Mechanisms of Neurodegenerative Diseases: The Pivotal Role of PKCα Recombinant Rabbit Monoclonal Antibodies by ANT BIO PTE. LTD.

1. Concept

Protein kinase C alpha (PKCα) is a key member of the PKC family, functioning as a serine/threonine kinase and lipid peroxidation sensor. It participates in classical second messenger signal transduction and regulates cellular oxidative stress responses. In neurodegenerative diseases like Parkinson’s disease, PKCα plays a critical pathogenic role: iron overload and lipid peroxidation induce its upregulation in dopaminergic neurons, where it binds and phosphorylates 5-lipoxygenase (ALOX5) at serine 663. This activates ALOX5, triggering toxic lipid metabolite accumulation (e.g., 5-hydroxyeicosatetraenoic acid) and neuronal damage. PKCα recombinant rabbit monoclonal antibodies are indispensable tools for dissecting this regulatory mechanism and exploring therapeutic targets.

2. Research Frontiers

A key research frontier focuses on developing PKCα-ALOX5 axis-targeted therapies. Researchers are using PKCα antibodies to screen small molecules or natural compounds (e.g., clausenamide) that block PKCα-mediated ALOX5 phosphorylation, aiming to inhibit lipid peroxidation and neuronal loss.

Another active area of investigation involves expanding PKCα’s role in other neurodegenerative diseases (e.g., Alzheimer’s, amyotrophic lateral sclerosis). Antibodies are used to verify whether the PKCα-ALOX5 axis is universally involved in lipid peroxidation-driven neuronal damage across different disease models.

Emerging frontiers also include developing PKCα as a diagnostic biomarker. Studies explore whether PKCα expression or phosphorylation levels in cerebrospinal fluid or brain tissues correlate with disease progression, enabling early detection and treatment monitoring.

3. Research Significance

PKCα recombinant rabbit monoclonal antibodies hold profound significance for neurodegenerative disease research and clinical translation. In basic science, they uncover the PKCα-ALOX5 axis as a key link between oxidative stress and neuronal damage, advancing our understanding of disease pathogenesis. This addresses the lack of effective disease-modifying therapies for conditions like Parkinson’s disease.

Clinically, the antibody validates PKCα as a therapeutic target, supporting the development of targeted interventions. It also aids in drug efficacy evaluation and biomarker development, improving patient diagnosis, prognosis, and treatment outcomes. For natural compounds like clausenamide, the antibody accelerates preclinical research by confirming their mechanism of action.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

PKCα-ALOX5 Axis in Neurodegeneration

Under oxidative stress (e.g., ferroptosis induction), PKCα is upregulated and translocates to the membrane. As illustrated in the diagram, it binds ALOX5, phosphorylating serine 663 to promote ALOX5 nuclear translocation and enzymatic activation. ALOX5 catalyzes arachidonic acid metabolism, producing neurotoxic lipids that exacerbate membrane lipid peroxidation, forming a positive feedback loop leading to dopaminergic neuron dysfunction and death. Clausenamide blocks this axis by competitively binding ALOX5’s serine 663 site, inhibiting phosphorylation and neuronal damage.

Research Methods and Product Applications

PKCα recombinant rabbit monoclonal antibodies are versatile tools for neurodegenerative disease research. ANT BIO PTE. LTD.’s PKCα Recombinant Rabbit Monoclonal Antibody (Catalog No.: S0B0494) stands out for its high specificity, broad species reactivity, and multi-application compatibility, making it essential for mechanism studies and drug development.

Key Applications of the Antibody:

• Expression and Localization Analysis: Using WB, IHC, and IF, the antibody quantifies PKCα levels and cellular distribution in dopaminergic neurons (substantia nigra pars compacta) across disease stages.
• Interaction Network Studies: Combined with co-IP and mass spectrometry, it identifies PKCα-interacting proteins (e.g., ALOX5), mapping the molecular network in neurodegeneration.
• Phosphorylation Detection: Paired with phospho-specific antibodies, it assesses PKCα kinase activity and ALOX5 phosphorylation status.
• Drug Mechanism Validation: In interventions (e.g., clausenamide), the antibody evaluates drug effects on the PKCα-ALOX5 axis, confirming target engagement.
• Disease Model Validation: In Parkinson’s animal models, it validates the impact of genetic or pharmacological interventions on PKCα expression and function.

Core Advantages of the Antibody:

• High Specificity: Specifically recognizes PKCα with minimal cross-reactivity to other PKC isoforms (e.g., PKCβ, PKCγ), ensuring accurate target detection.
• Broad Species Reactivity: Cross-reacts with human, mouse, and rat PKCα, supporting cross-species research and translational studies.
• Multi-Platform Compatibility: Excels in WB, IP, IF, and IHC, enabling comprehensive analysis of protein expression, interactions, and localization.
• Batch Consistency: Produced via recombinant technology, ensuring stable performance across batches for reproducible results.

PKCα-ALOX5 Axis Regulatory Cascade:

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to advancing life science research and clinical diagnostics by providing high-performance, innovative core reagents and comprehensive solutions. Leveraging advanced development platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development platforms (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—the company adheres to stringent quality standards and has successfully obtained EU 98/79/EC certification, ISO9001 certification, and ISO13485 certification. ANT BIO PTE. LTD. strives to support researchers and clinicians worldwide in their pursuit of scientific breakthroughs, improved patient care, and the development of innovative therapies for neurodegenerative diseases.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.